Committee for Medicinal Products for Veterinary Use
Draft agenda of January 2017 meeting

Chair: David Murphy
Vice-chair: Helen Jukes

17 January 2017, 09:00 – 19 January 2017, 13:00 - Room 2A

Declaration of interests

In accordance with the Agency’s revised policy and procedure on the handling of competing interests, participants in this meeting are asked to declare any interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests). Discussions, deliberations and voting will take place in full respect of the restricted involvement of CVMP members and, where relevant, experts attending the plenary meeting, as announced by the CVMP Secretariat at the start of meeting.

Disclaimers

Some documents mentioned in the agenda/minutes cannot be released at present within the framework of Regulation (EC) No 1049/2001 on access to documents because they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

i. Adoption of the agenda
ii. CVMP delegates list of intended participation and identified conflicts of interests
iii. Declaration of contacts between members and companies with regard to points on the agenda
iv. Adoption of the minutes of the previous meeting
v. Confirmation of topics for rapporteur’s meetings and breakout sessions

Scientific Advice Working Party (room 2A)  
Tue 17 Jan 2017 16.30-20.00
1. ESTABLISHMENT OF MAXIMUM RESIDUE LIMITS

1.1 Opinions
• No items

1.2 Oral explanations and list of outstanding issues
• No items

1.3 List of questions
• No items

1.4 Re-examination of CVMP opinions
• No items

1.5 Other issues

- **Substance**
  EMEA/V/MRL/004333/FULL/0001
  Bovine species

  **For decision:** Update on the submission of the responses to the LoOI

2. COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS

2.1 Opinions
• No items

2.2 Oral explanations and list of outstanding issues
• No items

2.3 List of questions

- **Product**
  EMEA/V/C/004316/0000
  New antiparasitic product
  Cats

  **For adoption:** Scientific overview and list of questions, comments on product information

- **Product**
  EMEA/V/C/004422/0000
  New vaccine
  Chickens

  **For adoption:** Scientific overview and list of questions, comments on product information

2.4 Re-examination of CVMP opinions

- **RESPIPORC FLUpan H1N1**
  EMEA/V/C/003993/0000
  New inactivated viral vaccine for active immunisation of pigs against swine influenza caused by pandemic subtype H1N1v
  Pigs

  Rapp: to be appointed
  Co-rapp: to be appointed

  **For decision:** Appointment of rapporteur, co-rapporteur and peer reviewers

  **For discussion:** Request for re-examination from applicant
### 2.5 Other issues

- **Product**
  - EMEA/V/C/004375/0000
  - New product for a musculo-skeletal system indication
  - Dogs
  - **For endorsement:** Request for a clock stop extension of two months

- **For endorsement:** EPAR module scientific discussion for Coliprotec F4/F18 (EMEA/V/C/004225/0000)

### 3. VARIATIONS TO COMMUNITY MARKETING AUTHORISATIONS

#### 3.1 Opinions

<table>
<thead>
<tr>
<th>Product</th>
<th>Rapp: E.-M. Vestergaard</th>
<th><strong>For adoption:</strong> CVMP opinion, CVMP assessment report</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZULVAC 1+8 Ovis, ZULVAC 8 Ovis, ZULVAC 1+8 Bovis, ZULVAC 1 Ovis, ZULVAC 1 Bovis, ZULVAC 8 Bovis</td>
<td>Rapp: E.-M. Vestergaard</td>
<td><strong>For adoption:</strong> CVMP opinion, CVMP assessment report</td>
</tr>
<tr>
<td>EMEA/V/C/xxxxxx/WS1040 Quality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clomicalm, OSURNIA, ZOLVIX, Econor, FORTEKOR PLUS, Onsior, Prac-tic</td>
<td>Rapp: C. Ibrahim</td>
<td><strong>For adoption:</strong> CVMP opinion, CVMP assessment report</td>
</tr>
<tr>
<td>EMEA/V/C/xxxxxx/WS1074 Quality</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 3.2 Oral explanations and list of outstanding issues

- **NEXGARD SPECTRA**
  - EMEA/V/C/003842/II/0008
  - To add new therapeutic indications
  - Rapp: J. G. Beechinor
  - Co-rapp: S. Sric
  - **For adoption:** CVMP list of outstanding issues

- **Stronghold**
  - EMEA/V/C/000050/II/0055/G
  - Quality
  - Rapp: H. Jukes
  - **For adoption:** CVMP list of outstanding issues

#### 3.3 List of questions

- **Pexion**
  - EMEA/V/C/002543/II/0009
  - Changes to the SPC
  - Rapp: S. Louet
  - Co-rapp: H. Jukes
  - **For adoption:** CVMP list of questions
<table>
<thead>
<tr>
<th><strong>ZULVAC 8 Ovis, ZULVAC 1+8 Ovis, ZULVAC 1 Bovis, ZULVAC SBV, ZULVAC 1+8 Bovis, ZULVAC 1 Ovis, ZULVAC 8 Bovis</strong>&lt;br&gt;EMEA/V/C/xxxxxx/WS1039&lt;br&gt;Quality</th>
<th>Rapp: E.-M. Vestergaard&lt;br&gt;<em>For adoption:</em> CVMP list of questions</th>
</tr>
</thead>
</table>

3.4 **Re-examination of CVMP opinions**
- No items

3.5 **Other issues**
- No items

4. **REFERRALS AND RELATED PROCEDURES**

4.1 **Article 33 of Directive 2001/82/EC**
- No items

4.2 **Article 34 of Directive 2001/82/EC**
- No items

4.3 **Article 35 of Directive 2001/82/EC**

4.4 **Article 78 of Directive 2001/82/EC**
- No items
4.5  Article 13 of Regulation (EC) No 1234/2008

- No items

4.6  Article 30(3) of Regulation 726/2004

- No items

4.7  Other issues

- No items

5.  POST-AUTHORISATION ISSUES FOR COMMUNITY MARKETING AUTHORISATIONS (EXCLUDING VARIATIONS)

5.1  General issues

- No items

5.2  Post-authorisation measures and annual reassessments

<table>
<thead>
<tr>
<th>Product</th>
<th>Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simparica</td>
<td>Rapp: J. G. Beechinor</td>
</tr>
<tr>
<td>EMEA/V/C/003991/REC/008-010</td>
<td>Co-rapp: P. Hekman</td>
</tr>
<tr>
<td>ZOLVIX</td>
<td>Rapp: E.-M. Vestergaard</td>
</tr>
<tr>
<td>EMEA/V/C/000154/REC/011</td>
<td>Co-rapp: G. J. Schefferlie</td>
</tr>
<tr>
<td>For adoption: Rapporteur’s assessment report</td>
<td></td>
</tr>
</tbody>
</table>

5.3  Product anniversary list

<table>
<thead>
<tr>
<th>Product</th>
<th>Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acticam (EMEA/V/C/000138)</td>
<td>09/12/2015 – 08/12/2016</td>
</tr>
<tr>
<td>Imrestor (EMEA/V/C/002763)</td>
<td>09/12/2015 – 08/12/2016</td>
</tr>
<tr>
<td>Inflacam (EMEA/V/C/002497)</td>
<td>09/12/2015 – 08/12/2016</td>
</tr>
<tr>
<td>Panacur AquaSol (EMEA/V/C/002008)</td>
<td>09/12/2015 – 08/12/2016</td>
</tr>
<tr>
<td>SevoFlo (EMEA/V/C/000072)</td>
<td>11/12/2015 – 10/12/2016</td>
</tr>
<tr>
<td>Cepedex (EMEA/V/C/004376)</td>
<td>13/12/2015 – 12/12/2016</td>
</tr>
<tr>
<td>Onsiör (EMEA/V/C/000127)</td>
<td>16/12/2015 – 15/12/2016</td>
</tr>
<tr>
<td>BTVPUR (EMEA/V/C/002231)</td>
<td>17/12/2015 – 16/12/2016</td>
</tr>
<tr>
<td>BTVPUR AlSap 1 (EMEA/V/C/002230)</td>
<td>17/12/2015 – 16/12/2016</td>
</tr>
<tr>
<td>Prac-tic (EMEA/V/C/000103)</td>
<td>18/12/2015 – 17/12/2016</td>
</tr>
<tr>
<td>Bovela (EMEA/V/C/003703)</td>
<td>22/12/2015 – 21/12/2016</td>
</tr>
<tr>
<td>Metacam (EMEA/V/C/000033)</td>
<td>07/01/2016 – 06/01/2017</td>
</tr>
<tr>
<td>Activyl Tick Plus (EMEA/V/C/002234)</td>
<td>09/01/2016 – 08/01/2017</td>
</tr>
<tr>
<td>Product</td>
<td>Period</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>CORTAVANCE (EMEA/V/C/000110)</td>
<td>09/01/2016 – 08/01/2017</td>
</tr>
<tr>
<td>Rheumocam (EMEA/V/C/000121)</td>
<td>10/01/2016 – 09/01/2017</td>
</tr>
<tr>
<td>Ypozane (EMEA/V/C/000112)</td>
<td>11/01/2016 – 10/01/2017</td>
</tr>
<tr>
<td>Porcilis PCV (EMEA/V/C/000135)</td>
<td>12/01/2016 – 11/01/2017</td>
</tr>
<tr>
<td>Gripovac 3 (EMEA/V/C/000157)</td>
<td>14/01/2016 – 13/01/2017</td>
</tr>
<tr>
<td>RESPIPORC FLU3 (EMEA/V/C/000153)</td>
<td>14/01/2016 – 13/01/2017</td>
</tr>
<tr>
<td>MELOXIDYL (EMEA/V/C/000115)</td>
<td>15/01/2016 – 14/01/2017</td>
</tr>
<tr>
<td>NEXGARD SPECTRA (EMEA/V/C/003842)</td>
<td>15/01/2016 – 14/01/2017</td>
</tr>
<tr>
<td>ZULVAC 8 Bovis (EMEA/V/C/000145)</td>
<td>15/01/2016 – 14/01/2017</td>
</tr>
<tr>
<td>ZULVAC 8 Ovis (EMEA/V/C/000147)</td>
<td>15/01/2016 – 14/01/2017</td>
</tr>
</tbody>
</table>

5.4 Renewals

- **Nobivac L4**
  EMEA/V/C/002010/R/0007
  Rapp: B. Urbain
  Co-rapp: R. Breathnach
  *For adoption*: CVMP opinion, CVMP assessment report, product information

- **Porcilis Coliclos**
  EMEA/V/C/002011/R/0006
  Rapp: N. Garcia del Blanco
  Co-rapp: E. Werner
  *For adoption*: CVMP opinion, CVMP assessment report, product information

5.5 Pharmacovigilance - PSURs and SARs

- **Activyl**
  EMEA/V/C/000163
  Rapp: G. J. Schefferlie
  *For adoption*: CVMP assessment report on the PSUR for the period 01.09.15-31.08.16

- **Bovilis BTV8**
  EMEA/V/C/000148
  Rapp: P. Pasquali
  *For adoption*: CVMP assessment report on the PSUR for the period 01.10.15-30.10.16

- **Bravecto**
  EMEA/V/C/002526
  Rapp: G. J. Schefferlie
  *For adoption*: CVMP assessment report on the PSUR for the period 01.03.16-31.08.16
  *For discussion and decision*: Request for extension of deadline from MAH to submit targeted PSUR
<table>
<thead>
<tr>
<th>Product</th>
<th>Code</th>
<th>Rapp</th>
<th>Status</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Broadline</strong></td>
<td>EMEA/V/C/002700</td>
<td>B. Urbain</td>
<td><strong>For adoption</strong></td>
<td>CVMP assessment report on the PSUR for the period 01.01.16-30.06.16</td>
</tr>
<tr>
<td><strong>Clomicalm</strong></td>
<td>EMEA/V/C/000039</td>
<td>C. Ibrahim</td>
<td></td>
<td>CVMP assessment report on the PSUR for the period 01.08.13-31.07.16</td>
</tr>
<tr>
<td><strong>Neocolipor</strong></td>
<td>EMEA/V/C/000035</td>
<td>J.-C. Rouby</td>
<td></td>
<td>CVMP assessment report on the PSUR for the period 01.09.13-31.08.16</td>
</tr>
<tr>
<td><strong>Nobilis IB-91</strong></td>
<td>EMEA/V/C/000036</td>
<td>N. Garcia del Blanco</td>
<td></td>
<td>CVMP assessment report on the PSUR for the period 01.04.16-30.09.16</td>
</tr>
<tr>
<td><strong>Nobilis IB Primo QX</strong></td>
<td>EMEA/V/C/002802</td>
<td>N. Garcia del Blanco</td>
<td></td>
<td>CVMP assessment report on the PSUR for the period 01.04.16-30.09.16</td>
</tr>
<tr>
<td><strong>Novaquin</strong></td>
<td>EMEA/V/C/003866</td>
<td>J. G. Beechinor</td>
<td><strong>For adoption</strong></td>
<td>CVMP assessment report on the PSUR for the period 09.03.16-08.09.16</td>
</tr>
<tr>
<td><strong>Osurnia</strong></td>
<td>EMEA/V/C/003753</td>
<td>S. Louet</td>
<td><strong>For adoption</strong></td>
<td>CVMP assessment report on the PSUR for the period 01.02.16-31.07.16</td>
</tr>
<tr>
<td><strong>Pexion</strong></td>
<td>EMEA/V/C/002543</td>
<td>S. Louet</td>
<td><strong>For adoption</strong></td>
<td>CVMP assessment report on the PSUR for the period 01.09.15-31.08.16</td>
</tr>
<tr>
<td><strong>Semintra</strong></td>
<td>EMEA/V/C/002436</td>
<td>R. Breathnach</td>
<td></td>
<td>CVMP assessment report on the PSUR for the period 01.09.15-31.08.16</td>
</tr>
<tr>
<td><strong>STARTVAC</strong></td>
<td>EMEA/V/C/002436</td>
<td>E. Werner</td>
<td><strong>For discussion and adoption</strong></td>
<td>CVMP assessment report on the PSUR for the period 01.09.13-31.08.16</td>
</tr>
<tr>
<td><strong>Vectormune ND</strong></td>
<td>EMEA/V/C/003829</td>
<td>F. Klein</td>
<td><strong>For adoption</strong></td>
<td>CVMP assessment report on the PSUR for the period 01.04.16-30.09.16</td>
</tr>
<tr>
<td><strong>Versican Plus DHPPi</strong></td>
<td>EMEA/V/C/003679</td>
<td>E. Werner</td>
<td><strong>For discussion and adoption</strong></td>
<td>CVMP assessment report on the PSUR for the period 01.02.16-31.07.16</td>
</tr>
</tbody>
</table>
5.6 Supervision and sanctions

Information relating to GMP and pharmacovigilance inspections will not be published as it would be undermining the purpose of such inspections

6. CO-OPERATION WITH OTHER EU OR INTERNATIONAL BODIES

6.1 VICH

- **For endorsement**: Draft VICH GL on general principles for detection of extraneous viruses in veterinary vaccines and defining the testing of seeds and materials of animal origin; draft VICH GL on a list of extraneous viruses that need to be covered

- **For endorsement**: Need for review of VICH safety guidelines

- **For endorsement**: Draft EU response to EWG comments relating to ongoing discussions on the possibility of updating VICH GL22 on reproduction testing to allow use of the extended one generation reproductive toxicity study (EOGRST)

- **For information**: 34th VICH Steering Committee meeting and Outreach Forum meeting to be held on 27 February to 2 March 2017 in Buenos Aires, Argentina; draft Steering Committee agenda, draft Outreach Forum agenda and minutes of the 33rd VICH Steering Committee held on 21-24 June 2016

- **For endorsement**: PhV Electronic Standards Implementation EWG - comments on industry document on disharmony in the field of pharmacovigilance

6.2 Codex Alimentarius

- **For information**: Feedback from the Codex Committee on Residues of Veterinary Drugs in Foods (CCRVDF) meeting held on 17-21 October 2016 in Houston, USA; report of the meeting

6.3 Other EU bodies and international organisations

- **For information**: Verbal report from the 2nd EMA/JECFA liaison meeting held on 26 September 2016

- **For decision**: EFSA Workshop on Benchmark Dose to be held on 1-2 March 2017 in Brussels; draft programme

- **For information**: EFSA 2nd report on ‘Chemicals in food 2016; overview of selected data collection’ (link); detailed report on residues of veterinary medicines (link)
7. WORKING PARTIES AND SCIENTIFIC ADVISORY GROUPS

Information on certain topics discussed under section 7 cannot be released at the present time as it is deemed to be confidential.

7.1 Scientific Advice Working Party (SAWP-V)

Information relating to SAWP procedures cannot be released at the present time as it is deemed to be commercially confidential.

7.2 Quality Working Party (QWP)

7.3 Safety Working Party (SWP-V)

7.4 Environmental Risk Assessment Working Party (ERAWP)

7.5 Efficacy Working Party (EWP-V)

7.6 Antimicrobials Working Party (AWP)

7.7 Immunologicals Working Party (IWP)

7.8 Pharmacovigilance Working Party (PhVWP-V)

7.9 Novel therapy groups and related issues

7.10 Joint CVMP/CHMP AHEG on the application of the 3Rs

7.11 Other working party and scientific group issues

8. OTHER SCIENTIFIC MATTERS

8.1 MRLs issues

Information on certain MRL related issues cannot be released at the present time as it is deemed to be confidential.

- No items

8.2 Environmental risk assessment

Information on certain environmental risk assessment related issues cannot be released at the present time as it is deemed to be confidential.

8.3 Antimicrobial resistance

Information relating to items under 8.3 cannot be released at the present time as it is deemed to be commercially confidential.

8.4 Pharmacovigilance

- No items

8.5 Other issues

Information on other critical issues related to centralised procedures cannot be released at the present time as it is deemed to be commercially confidential.
9. AVAILABILITY OF MEDICINES AND MUMS CLASSIFICATION

Information relating to availability of medicines cannot be released at the present time as it is deemed to be commercially confidential

- For information: Network action plan on availability of veterinary vaccines – meeting with industry stakeholders held on 8 December 2016: agenda and draft minutes
- For decision: Request for a breakout session between CVMP and FishMedPlus Coalition in the margins of a future CVMP meeting
- For information: Stakeholder focus group meeting on availability of Lumpy Skin Disease (LSD) vaccines authorised to EU standards – draft agenda

10. PROCEDURAL AND REGULATORY MATTERS

10.1 Eligibility and appointment of rapporteurs, co-rapporteurs and peer reviewers

Information relating to notification of intent for new MRL applications and notification of intent and eligibility requests for community marketing authorisations cannot be released at the present time as it is deemed to be commercially confidential

10.2 Regulatory matters

Information relating to certain regulatory issues cannot be released at the present time as it is deemed to be commercially confidential

11. CO-ORDINATION GROUP FOR MUTUAL RECOGNITION AND DECENTRALISED PROCEDURES

- For information: Draft agenda of the meeting to be held on 19-20 January 2017, draft minutes of meeting held on 8-9 December 2016, presentation

12. ORGANISATIONAL AND STRATEGIC MATTERS

- For discussion: CVMP operation and procedures: practical guidance document for CVMP members
- For discussion: Guidance to applicants on oral explanations
- For discussion: Appointment of rapporteurs for CVMP procedures – next steps; verbal report from the break-out session
- For information: Verbal report from the chair on the Strategic Planning Group (SPG) meeting to be held on 18 January 2017, draft agenda; draft minutes from the SPG meeting held on 5 October 2016
- For information: Request from Swissmedic for regular observer participation in CVMP meetings

13. LEGISLATION

- To note: Commission Implementing Regulation (EU) 2017/12 of 6 January 2017 regarding the form and content of the applications and requests for the establishment of maximum residue limits in accordance with Regulation (EC) No 470/2009 (link)

14. ANY OTHER BUSINESS

- For comments: Press release of the meeting
ANNEX

Next meetings of the CVMP and its working parties

<table>
<thead>
<tr>
<th></th>
<th>CVMP</th>
<th>ADVENT</th>
<th>AWP</th>
<th>ERAWP</th>
<th>EWP</th>
<th>IWP</th>
<th>PhVWP</th>
<th>QWP</th>
<th>SAWP</th>
<th>SWP</th>
<th>3R's</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan 2017</td>
<td>17-19</td>
<td></td>
<td>31-1</td>
<td></td>
<td>24-25</td>
<td>31-2</td>
<td></td>
<td>17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feb 2017</td>
<td>14-16</td>
<td>16</td>
<td>28-1</td>
<td>21-22</td>
<td>1-2</td>
<td></td>
<td>14</td>
<td>2-3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mar 2017</td>
<td>14-16</td>
<td></td>
<td></td>
<td>21-22</td>
<td></td>
<td></td>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apr 2017</td>
<td>10-12*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10</td>
<td>26-27</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 2017</td>
<td>10-12**</td>
<td>12</td>
<td>23-24</td>
<td>30-31</td>
<td>16-17</td>
<td>22-24</td>
<td>10</td>
<td>18-19</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Monday to Wednesday

**Wednesday to Friday